Your browser doesn't support javascript.
loading
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan; Gilbert, Judith A; Cafourek, Victoria; Hillman, David W; Elkhanany, Ahmed; Akinhanmi, Margaret; Lilyquist, Jenna; Thomas, Abigail; Negron, Vivian; Boughey, Judy C; Liu, Minetta C; Ingle, James N; Kalari, Krishna R; Couch, Fergus J; Visscher, Daniel W; Goetz, Matthew P.
Afiliação
  • Leon-Ferre RA; Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Polley MY; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Liu H; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Gilbert JA; Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Cafourek V; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Hillman DW; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Elkhanany A; Hematology/Oncology, Roswell Park, Buffalo, NY, USA.
  • Akinhanmi M; Graduate School of Biomedical Science, Mayo Clinic, Rochester, MN, USA.
  • Lilyquist J; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Thomas A; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Negron V; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Boughey JC; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Liu MC; Surgery, Mayo Clinic, Rochester, MN, USA.
  • Ingle JN; Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Kalari KR; Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Couch FJ; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Visscher DW; Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Goetz MP; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Breast Cancer Res Treat ; 167(1): 89-99, 2018 01.
Article em En | MEDLINE | ID: mdl-28913760
ABSTRACT

BACKGROUND:

Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown.

METHODS:

From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs. The impact of these parameters on invasive disease-free survival (IDFS) and overall survival (OS) was assessed using Cox proportional hazards models.

RESULTS:

Six hundred five patients met the criteria for TNBC (ER/PR < 1% and HER2 negative). Most were T1-2 (95%), N0-1 (86%), grade 3 (88%), and had a Ki-67 >15% (75%). Histologically, 70% were invasive carcinoma of no special type, 16% medullary, 8% metaplastic, and 6% apocrine. The median stromal TIL content was 20%. Four hundred twenty-three (70%) patients received adjuvant chemotherapy. Median OS follow-up was 10.6 years. On multivariate analysis, only higher nodal stage, lower TILs, and the absence of adjuvant chemotherapy were associated with worse IDFS and OS. Among systemically untreated patients (n = 182), the 5-year IDFS was 69.9% (95% CI 60.7-80.5) [T1a 82.5% (95% CI 62.8-100), T1b 67.5% (95% CI 51.9-87.8) and T1c 67.3% (95% CI 54.9-82.6)], compared to 77.8% (95% CI 68.3-83.6) for systemically treated T1N0. Nodal stage and TILs remained strongly associated with outcomes.

CONCLUSIONS:

In early-stage TNBC, nodal involvement, TILs, and receipt of adjuvant chemotherapy were independently associated with IDFS and OS. In systemically untreated TNBC, TILs remained prognostic and the risk of recurrence or death was substantial, even for T1N0 disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Linfócitos do Interstício Tumoral / Neoplasias de Mama Triplo Negativas / Recidiva Local de Neoplasia Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Linfócitos do Interstício Tumoral / Neoplasias de Mama Triplo Negativas / Recidiva Local de Neoplasia Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2018 Tipo de documento: Article